Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China

Abstract The combination of venetoclax (VEN) and azacitidine (AZA) has transformed the treatment of acute myeloid leukemia (AML) in patients ineligible for intensive therapy. Nevertheless, real-world evidence on long-term outcomes in patients with AML treated with VEN + AZA remains limited. A retros...

Descripció completa

Dades bibliogràfiques

Autors principals:	Xuexing Chen, Qiong Yan, Chunfang Li, Fei Liu, Shaojun Guo, Juan Zhao, Yan Liang, Haiyan Wang, Weiming Li, Guolin Yuan
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2026-04-01
Col·lecció:	Scientific Reports
Matèries:	Venetoclax Acute myeloid leukemia Long-term treatment Efficacy Prognostic factors
Accés en línia:	https://doi.org/10.1038/s41598-026-50426-0
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!